ReviewCurrent infectious disease reports2020
Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis.
Review in Current infectious disease reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Systems-level restoration of vaginal and gut microbiota by Lactobacillus helveticus 20838 alleviates Gardnerella vaginalis-induced dysbiosis.The ISME journal · 2026Article
- Prevalence and Accuracy of Empiric Treatment Among Patients With Vaginitis Symptoms in the United States.Sexually transmitted diseases · 2025Article
- Genital cutaneous candidiasis versus chronic recurrent vulvovaginal candidiasis: distinct diseases, different populations.Clinical microbiology reviews · 2025Review
- A Fungistatic Strategy Using a Shear-Thinning pH-Responsive CMCS-OHA-Lp/Lr Hydrogel for Vulvovaginal Candidiasis.Pharmaceutics · 2025Article
- Antimicrobial and anti-biofilm properties of oleuropein against Escherichia coli and fluconazole-resistant isolates of Candida albicans and Candida glabrata.BMC microbiology · 2024Article
- Article
- Lived experience of medical management in recurrent vulvovaginal candidiasis: a qualitative study of an uncertain journey.BMC women's health · 2022Article
- New Peptide Based Fluconazole Conjugates with Expanded Molecular Targets.Pharmaceutics · 2022Article
- Current and promising pharmacotherapeutic options for candidiasis.Expert opinion on pharmacotherapy · 2021Article
- New Approach to Antifungal Activity of Fluconazole Incorporated into the Porous 6-Anhydro-α-l-Galacto-β-d-Galactan Structures Modified with Nanohydroxyapatite for Chronic-Wound Treatments-In Vitro Evaluation.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to broad spectrum susceptibility of Candida species to fluconazole, its convenience as an oral agent, and predictable patient tolerance and safety, current practice guidelines recommend the use of long-term suppression regimens of fluconazole as prophylaxis for recurrent vulvovaginal candidiasis (RVVC), as well as in abbreviated doses when known trigger factors emerge and inevitable symptomatic episodes are predictable. However, recent concerns of fluconazole-resistant Candida albicans strains may impact fluconazole use, particularly, concerns of overuse. This literature review discusses current recommendations for prophylaxis of vulvovaginal candidiasis with fluconazole.
Indexed as
Identifiers
31965356What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.